NR1H4 and Hepatic fibrosis: These findings may in part explain the beneficial effects on hepatic fibrosis in recent phase 3 clinical trials with OCA in patients suffering from PBC and NASH and support extending clinical trials with FXR agonists to other forms of chronic liver injury51, 52.